Signaturefd LLC Purchases 165 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Signaturefd LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,801 shares of the company’s stock after buying an additional 165 shares during the quarter. Signaturefd LLC’s holdings in Neurocrine Biosciences were worth $382,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in NBIX. CIBC Asset Management Inc grew its position in shares of Neurocrine Biosciences by 5.6% in the third quarter. CIBC Asset Management Inc now owns 3,591 shares of the company’s stock valued at $414,000 after purchasing an additional 191 shares in the last quarter. Swiss National Bank grew its position in shares of Neurocrine Biosciences by 1.4% in the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after purchasing an additional 4,100 shares in the last quarter. Quest Partners LLC grew its position in shares of Neurocrine Biosciences by 674.9% in the third quarter. Quest Partners LLC now owns 3,495 shares of the company’s stock valued at $403,000 after purchasing an additional 3,044 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Neurocrine Biosciences in the third quarter valued at $553,000. Finally, Commerce Bank grew its position in shares of Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after purchasing an additional 108 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CFO Matt Abernethy sold 2,558 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.86, for a total transaction of $298,927.88. Following the completion of the transaction, the chief financial officer now owns 34,775 shares of the company’s stock, valued at $4,063,806.50. This represents a 6.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.92, for a total value of $413,954.44. Following the transaction, the director now directly owns 517,030 shares of the company’s stock, valued at $79,064,227.60. The trade was a 0.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 233,178 shares of company stock valued at $33,906,594 in the last 90 days. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Down 0.2 %

NASDAQ NBIX opened at $110.07 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $105.18 and a 1-year high of $157.98. The stock has a 50-day moving average of $127.48 and a 200-day moving average of $125.25. The firm has a market cap of $10.97 billion, a PE ratio of 33.46, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. As a group, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences declared that its board has approved a share repurchase plan on Friday, February 21st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to reacquire up to 4.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Morgan Stanley reiterated an “overweight” rating and issued a $150.00 price target (down from $185.00) on shares of Neurocrine Biosciences in a research report on Friday, March 7th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Wedbush reduced their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. UBS Group boosted their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Finally, Bank of America reduced their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $165.24.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.